What is it about?
Mesenchymal stem cells (MSCs) have shown their positions in treatment of diabetic complications, but how do antidiabetic drugs change the behavior of MSCs in diabetic conditions? This paper investigates effects of metformin and celecoxib on viability of MSCs and release of GDF-15 from MSCs in different glucose conditins.
Featured Image
Why is it important?
Our findings show that metformin treatment reduced viability of MSCs, but its toxicity was not changed in high glucose condition. On the other hand, celecoxib induced cytotoxicity in MSCs, and the toxicity was increased in high glucose condition. Perhaps change in release of GDF-15 from MSCs by antidiabetic drugs play a role in cytotoxic effects of them.
Perspectives
I hope this article create new perspective in application of MSCs in treatment of diabetic patients who suffer from diabetic complications.
Elaheh Zafarvahedian
Tehran University of Medical Sciences
Read the Original
This page is a summary of: Effect of metformin and celecoxib on cytotoxicity and release of GDF-15 from human mesenchymal stem cells in high glucose condition, Cell Biochemistry and Function, October 2017, Wiley,
DOI: 10.1002/cbf.3289.
You can read the full text:
Contributors
The following have contributed to this page
